- Home
- CCEL vs SER Comparison
CCEL vs SER Comparison
Compare CCEL & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- SER
- Stock Information
- Founded
- CCEL 1989
- SER 2017
- Country
- CCEL United States
- SER United States
- Employees
- CCEL N/A
- SER N/A
- Industry
- CCEL Managed Health Care
- SER Biotechnology: Pharmaceutical Preparations
- Sector
- CCEL Health Care
- SER Health Care
- Exchange
- CCEL Nasdaq
- SER Nasdaq
- Market Cap
- CCEL 51.9M
- SER 56.5M
- IPO Year
- CCEL 1997
- SER 2018
- Fundamental
- Price
- CCEL $5.12
- SER $6.00
- Analyst Decision
- CCEL Strong Buy
- SER Strong Buy
- Analyst Count
- CCEL 1
- SER 1
- Target Price
- CCEL $8.50
- SER $11.00
- AVG Volume (30 Days)
- CCEL 10.1K
- SER 9.3K
- Earning Date
- CCEL 07-14-2025
- SER 05-08-2025
- Dividend Yield
- CCEL 7.81%
- SER N/A
- EPS Growth
- CCEL N/A
- SER N/A
- EPS
- CCEL 0.01
- SER N/A
- Revenue
- CCEL $32,102,750.00
- SER $51,000.00
- Revenue This Year
- CCEL $2.49
- SER N/A
- Revenue Next Year
- CCEL $0.95
- SER N/A
- P/E Ratio
- CCEL $321.51
- SER N/A
- Revenue Growth
- CCEL 2.33
- SER N/A
- 52 Week Low
- CCEL $4.75
- SER $3.81
- 52 Week High
- CCEL $9.43
- SER $14.57
- Technical
- Relative Strength Index (RSI)
- CCEL 48.65
- SER 57.10
- Support Level
- CCEL $4.79
- SER $5.01
- Resistance Level
- CCEL $5.15
- SER $6.00
- Average True Range (ATR)
- CCEL 0.17
- SER 0.34
- MACD
- CCEL 0.05
- SER 0.00
- Stochastic Oscillator
- CCEL 63.79
- SER 90.83
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.